Lilly's experimental drug outperforms Zepbound in weight-loss trial
Eli Lilly's experimental combination weight-loss drug showed superior results compared to its own blockbuster Zepbound in a head-to-head trial, increasing competition with Novo Nordisk for obesity therapies.